155 related articles for article (PubMed ID: 8360879)
1. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids.
Kubo K; Kohara Y; Yoshimura Y; Inada Y; Shibouta Y; Furukawa Y; Kato T; Nishikawa K; Naka T
J Med Chem; 1993 Aug; 36(16):2343-9. PubMed ID: 8360879
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy)-ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5- yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116).
Shibouta Y; Inada Y; Ojima M; Wada T; Noda M; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
J Pharmacol Exp Ther; 1993 Jul; 266(1):114-20. PubMed ID: 8331552
[TBL] [Abstract][Full Text] [Related]
3. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazolecarboxylic acids.
Kubo K; Kohara Y; Imamiya E; Sugiura Y; Inada Y; Furukawa Y; Nishikawa K; Naka T
J Med Chem; 1993 Jul; 36(15):2182-95. PubMed ID: 8340921
[TBL] [Abstract][Full Text] [Related]
4. Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of benzimidazoles.
Kubo K; Inada Y; Kohara Y; Sugiura Y; Ojima M; Itoh K; Furukawa Y; Nishikawa K; Naka T
J Med Chem; 1993 Jun; 36(12):1772-84. PubMed ID: 8510105
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (+-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H- benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats.
Inada Y; Wada T; Shibouta Y; Ojima M; Sanada T; Ohtsuki K; Itoh K; Kubo K; Kohara Y; Naka T
J Pharmacol Exp Ther; 1994 Mar; 268(3):1540-7. PubMed ID: 8138966
[TBL] [Abstract][Full Text] [Related]
6. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate. Part I: Effects on central nervous system and other properties.
Kito G; Morimoto S; Shiomi M
Arzneimittelforschung; 1996 Jun; 46(6):572-9. PubMed ID: 8767346
[TBL] [Abstract][Full Text] [Related]
7. Effects of TCV-116 and CV-11974 on angiotensin II-induced responses in vascular smooth muscle cells.
Flesch M; Ko Y; Seul C; Düsing R; Feltkamp H; Vetter H; Sachinidis A
Eur J Pharmacol; 1995 Apr; 289(2):399-402. PubMed ID: 7621917
[TBL] [Abstract][Full Text] [Related]
8. Dihydropyrimidine angiotensin II receptor antagonists.
Atwal KS; Ahmed SZ; Bird JE; Delaney CL; Dickinson KE; Ferrara FN; Hedberg A; Miller AV; Moreland S; O'Reilly BC
J Med Chem; 1992 Dec; 35(25):4751-63. PubMed ID: 1469703
[TBL] [Abstract][Full Text] [Related]
9. Studies on nonpeptide angiotensin II receptor antagonists. IV. Synthesis and biological evaluation of 4-acrylamide-1H-imidazole derivatives.
Okazaki T; Watanabe T; Kikuchi K; Suga A; Shibasaki M; Fujimori A; Inagaki O; Yanagisawa I
Chem Pharm Bull (Tokyo); 1998 Jun; 46(6):973-81. PubMed ID: 9658576
[TBL] [Abstract][Full Text] [Related]
10. The angiotensin receptor antagonist 2-ethoxy-1-[[2'-(1H- tetrazol-5-yl) biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV11974) attenuates the tubuloglomerular feedback response during NO synthase blockade in rats.
Kawata T; Hashimoto S; Koike T
J Pharmacol Exp Ther; 1996 May; 277(2):572-7. PubMed ID: 8627533
[TBL] [Abstract][Full Text] [Related]
11. General pharmacological properties of the new angiotensin II receptor antagonist (+/-)-1-(cyclohexyloxycarbonyloxy) ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]-1 H-benzimidazole-7-carboxylate. Part II: Effect on cardiovascular system and renal functions.
Kito G; Ito K; Shiomi M
Arzneimittelforschung; 1996 Jul; 46(7):681-6. PubMed ID: 8842337
[TBL] [Abstract][Full Text] [Related]
12. CV-11974, the active metabolite of TCV-116 (Candesarten), inhibits the synergistic or additive effect of different growth factors on angiotensin II-induced proliferation of vascular smooth muscle cells.
Sachinidis A; el-Haschimi K; Ko Y; Seul C; Düsing R; Vetter H
Biochem Pharmacol; 1996 Jul; 52(1):123-6. PubMed ID: 8678895
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carboxylic acid (CI-996).
Sircar I; Hodges JC; Quin J; Bunker AM; Winters RT; Edmunds JJ; Kostlan CR; Connolly C; Kesten SJ; Hamby JM
J Med Chem; 1993 Aug; 36(16):2253-65. PubMed ID: 8360871
[TBL] [Abstract][Full Text] [Related]
14. A new class of diacidic nonpeptide angiotensin II receptor antagonists: candesartan cilexetil.
Naka T; Kubo K
Curr Pharm Des; 1999 Jun; 5(6):453-72. PubMed ID: 10390609
[TBL] [Abstract][Full Text] [Related]
15. Rationale for the chemical development of angiotensin II receptor antagonists.
Wexler RR; Carini DJ; Duncia JV; Johnson AL; Wells GJ; Chiu AT; Wong PC; Timmermans PB
Am J Hypertens; 1992 Dec; 5(12 Pt 2):209S-220S. PubMed ID: 1290616
[TBL] [Abstract][Full Text] [Related]
16. Sulfonylureas and sulfonylcarbamates as new non-tetrazole angiotensin II receptor antagonists. Discovery of a highly potent orally active (imidazolylbiphenylyl)sulfonylurea (HR 720).
Deprez P; Guillaume J; Becker R; Corbier A; Didierlaurent S; Fortin M; Frechet D; Hamon G; Heckmann B; Heitsch H
J Med Chem; 1995 Jun; 38(13):2357-77. PubMed ID: 7608902
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of rabbit aortic angiotensin II (AII) receptor by CV-11974, a new nonpeptide AII antagonist.
Noda M; Shibouta Y; Inada Y; Ojima M; Wada T; Sanada T; Kubo K; Kohara Y; Naka T; Nishikawa K
Biochem Pharmacol; 1993 Jul; 46(2):311-8. PubMed ID: 8347154
[TBL] [Abstract][Full Text] [Related]
18. Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates.
Ashton WT; Hutchins SM; Greenlee WJ; Doss GA; Chang RS; Lotti VJ; Faust KA; Chen TB; Zingaro GJ; Kivlighn SD
J Med Chem; 1993 Nov; 36(23):3595-605. PubMed ID: 8246227
[TBL] [Abstract][Full Text] [Related]
19. Functional evidence for the ability of angiotensin AT1 receptor antagonists to cross the blood-brain barrier in rats.
Polidori C; Ciccocioppo R; Pompei P; Cirillo R; Massi M
Eur J Pharmacol; 1996 Jul; 307(3):259-67. PubMed ID: 8836613
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and SAR studies of novel triazolopyrimidine derivatives as potent, orally active angiotensin II receptor antagonists.
Nicolaï E; Curé G; Goyard J; Kirchner M; Teulon JM; Versigny A; Cazes M; Caussade F; Virone-Oddos A; Cloarec A
J Med Chem; 1994 Jul; 37(15):2371-86. PubMed ID: 8057285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
